CN104083556A - Method for extracting konjak ceramide from konjak - Google Patents
Method for extracting konjak ceramide from konjak Download PDFInfo
- Publication number
- CN104083556A CN104083556A CN201410336065.3A CN201410336065A CN104083556A CN 104083556 A CN104083556 A CN 104083556A CN 201410336065 A CN201410336065 A CN 201410336065A CN 104083556 A CN104083556 A CN 104083556A
- Authority
- CN
- China
- Prior art keywords
- extraction
- pressure
- separating still
- rhizoma amorphophalli
- kettle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940106189 ceramide Drugs 0.000 title claims abstract description 40
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 title claims abstract description 38
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 title claims abstract description 38
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 title claims abstract description 38
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 229920002752 Konjac Polymers 0.000 title claims abstract description 26
- 235000010485 konjac Nutrition 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims abstract description 26
- 238000000605 extraction Methods 0.000 claims abstract description 95
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 60
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000007788 liquid Substances 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 12
- 229910002092 carbon dioxide Inorganic materials 0.000 claims abstract description 8
- 230000004087 circulation Effects 0.000 claims abstract description 8
- 239000001569 carbon dioxide Substances 0.000 claims abstract description 7
- 238000003860 storage Methods 0.000 claims abstract description 7
- 239000000284 extract Substances 0.000 claims description 27
- 239000008187 granular material Substances 0.000 claims description 10
- 238000007664 blowing Methods 0.000 claims description 5
- 230000001351 cycling effect Effects 0.000 claims description 5
- 238000005057 refrigeration Methods 0.000 claims description 5
- 238000000926 separation method Methods 0.000 abstract description 12
- NPRJSFWNFTXXQC-QFWQFVLDSA-N N-(hexanoyl)sphing-4-enine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(=O)CCCCC NPRJSFWNFTXXQC-QFWQFVLDSA-N 0.000 abstract description 3
- 238000007599 discharging Methods 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 238000010992 reflux Methods 0.000 description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000000287 crude extract Substances 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- XIRNKXNNONJFQO-UHFFFAOYSA-N ethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC XIRNKXNNONJFQO-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229940031439 squalene Drugs 0.000 description 6
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 4
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 4
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 4
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000012567 medical material Substances 0.000 description 4
- 238000000638 solvent extraction Methods 0.000 description 4
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 4
- 229940032091 stigmasterol Drugs 0.000 description 4
- 235000016831 stigmasterol Nutrition 0.000 description 4
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 4
- LVGKNOAMLMIIKO-VAWYXSNFSA-N 9-Octadecenoic acid, ethyl ester Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-VAWYXSNFSA-N 0.000 description 3
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 244000046052 Phaseolus vulgaris Species 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 229940067592 ethyl palmitate Drugs 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- -1 sphingolipid compound Chemical class 0.000 description 3
- 238000000194 supercritical-fluid extraction Methods 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 2
- 239000001149 (9Z,12Z)-octadeca-9,12-dienoate Substances 0.000 description 2
- WTTJVINHCBCLGX-UHFFFAOYSA-N (9trans,12cis)-methyl linoleate Natural products CCCCCC=CCC=CCCCCCCCC(=O)OC WTTJVINHCBCLGX-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- LNJCGNRKWOHFFV-UHFFFAOYSA-N 3-(2-hydroxyethylsulfanyl)propanenitrile Chemical compound OCCSCCC#N LNJCGNRKWOHFFV-UHFFFAOYSA-N 0.000 description 2
- 241001278826 Amorphophallus Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 244000205754 Colocasia esculenta Species 0.000 description 2
- 235000006481 Colocasia esculenta Nutrition 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- PKIXXJPMNDDDOS-UHFFFAOYSA-N Methyl linoleate Natural products CCCCC=CCCC=CCCCCCCCC(=O)OC PKIXXJPMNDDDOS-UHFFFAOYSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- MGWAVDBGNNKXQV-UHFFFAOYSA-N diisobutyl phthalate Chemical group CC(C)COC(=O)C1=CC=CC=C1C(=O)OCC(C)C MGWAVDBGNNKXQV-UHFFFAOYSA-N 0.000 description 2
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 2
- 229940031016 ethyl linoleate Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- HITROERJXNWVOI-SOFGYWHQSA-N (5e)-octa-1,5-diene Chemical compound CC\C=C\CCC=C HITROERJXNWVOI-SOFGYWHQSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 241000209524 Araceae Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010018286 Gingival pain Diseases 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Extraction Or Liquid Replacement (AREA)
Abstract
The invention discloses a method for extracting konjak ceramide from konjak. The method comprises the following steps: (1) crushing konjak into fine powder, adding ethanol, controlling the material-liquid ratio to be 1.5:(500-1200)Kg/ml, and granulating; (2) adding konjak grains prepared in the step (1) into an extraction kettle of supercritical CO2 extraction equipment, heating the extraction kettle, a separation kettle I and a separation kettle II, refrigerating a refrigerator and a storage tank, opening a carbon dioxide bottle when the temperature of the extraction kettle is 30-70 DEG C, the temperature of the separation kettle I is 40-65 DEG C and the temperature of the separation kettle II is 30-60 DEG C, pressurizing the extraction kettle and the separation kettle by a high-pressure pump, closing the carbon dioxide bottle when the pressure of the extraction kettle is 20-40MPa, the pressure of the separation kettle I is 6-18MPa and the pressure of the separation kettle II is 4-7MPa, opening a circulation valve for extracting circulation, discharging from the separation kettles I and II respectively every 30 minutes of circulation, and circularly extracting for 1-2 hours. The yield of C6-ceramide extracted by the method is high, and the extracted product has higher quality.
Description
Technical field
The present invention relates to extraction and separation technology field, relate in particular to a kind of method of extracting konjak ceramide from Rhizoma amorphophalli.
Background technology
Rhizoma amorphophalli (konjac) belongs to the herbal tuber of Araeceae (Araceae) Amorphophallus (Amorphophallus B1.ex Decne.), have another name called mill taro, terrible taro, ghost head, flower lotus bar, Rhizoma Amorphophalli etc., mainly originate in the torrid zone, the Eastern Hemisphere, subtropical zone, in China, have more widely and distribute.Rhizoma amorphophalli is cold in nature, pungent, poisonous; Can blood circulation promoting and blood stasis dispelling, removing toxic substances and promoting subsidence of swelling, wide intestinal relieving constipation, resolving phlegm and softening hard masses; Cure mainly the diseases such as blood pressure lowering, blood sugar lowering, scrofula sucutaneous nodule, damage congestive edema, constipation stomachache, laryngopharynx swelling and pain, gingival swelling and pain.
Ceramide type compound (Ceramide), N-fatty acyl-sphingosine, is the compounds being formed by sphingosine (sphingosine) and long-chain fatty acid condensation, is most important a kind of in sphingolipid compound.Ceramide is emerging a kind of active component recent years, contains than more rich ceramide in Rhizoma amorphophalli, and the content of its ceramide, up to 0.15~0.2%, is that currently used raw material is as 10 times of the raw materials such as Testa oryzae, Semen sojae atricolor, Semen Tritici aestivi.
What extraction ceramide was the most frequently used is organic solvent extraction, conventionally adopts isopropyl alcohol, ethyl acetate or chloroform extraction.Liu Renping etc., when exploring reflux extraction extraction konjak ceramide, find that the extraction effect of medium polar solvent ethyl acetate is the most desirable under the same conditions.But, under identical extraction conditions, with 95% ethanol extraction, by the effect of petroleum ether extraction and the extraction effect of ethyl acetate, be more or less the same, and ethyl acetate price is higher, in leaching process, volatilize larger, therefore, adopt 95% ethanol as extracting solvent.Author determines that by orthogonal test the optimised process extracting is 95% ethanol, extracts 80 ℃ of temperature, extraction time 8h, solid-liquid ratio 1:10, and the highest extracted amount reaches 4.34mg/g.
Urge splendid sunshine etc., adopt 95% ethanol, solid-liquid ratio 1:7.5,80 ℃~90 ℃ of bath temperatures, extraction time 8h~10h, adjusts extracting solution ethanol solubility to 70% with deionized water, petroleum ether extraction, Rotary Evaporators is concentrated.Concentrated solution is with petroleum ether: acetone (7:3) 200ml carries out 2 separation and purification of silica gel column chromatography, flow velocity is 1d/s, eluent is concentrated with Rotary Evaporators, concentrated solution carries out vacuum lyophilization and obtains white crude product, crude product carries out purification with acetone recrystallization, obtains the ceramide sample of white purification.
Wait quietly Wei Different Extraction Method to analyze mensuration, result shows that the content that solvent extraction method is measured under similar condition is 1.93%, and the content that supercritical ultrasonics technology records is 2.24%, and the latter's extraction effect is obviously better than the former.Author adopts experiments of single factor to analyze the principal element of the amide extraction ratio that affects the nerves, and utilizes orthogonal experiment to optimize the optimum process condition that extracts ceramide.Research shows, the optimum condition of supersound extraction konjak ceramide is: concentration of alcohol 95%, feed liquid mass ratio is 1:4, extracts temperature 60 C, extraction time 35min.Under this condition, the extraction ratio of ceramide crude extract is 2.89%.
Though the application that supercritical extraction technique extracts in ceramide at Rhizoma amorphophalli there is not yet report, Li Jia has applied this technology in microorganisms ferment rice bran is prepared ceramide, is indicating that supercritical extraction technique will extract ceramide at Rhizoma amorphophalli and be applied.Li Jia utilizes sphingomyelinase to make the content of ceramide free in Testa oryzae improve more than 3 times, and take extracting pressure as 30MPa, 32 ℃~35 ℃ of extraction temperature, separating still pressure is 7MPa~8MPa, the condition that temperature is 35 ℃~38 ℃ is carried out supercritical extraction and is obtained best effect of extracting.
Konjak ceramide is plant source ceramide, and safe in animal sources ceramide and synthetic ceramide, content is also originated higher than other plant.From existing document, the research of konjak ceramide is mainly concentrated on to its pharmacologically active aspect, and it extracts separation and quality analysis aspect is less, and extraction separation method tradition is loaded down with trivial details, the inadequate system of analytical method is comprehensive, also has no the supercritical CO of its ceramide
2extraction process research.
Summary of the invention
The invention provides a kind of method of extracting konjak ceramide from Rhizoma amorphophalli.
The present invention adopts following technical scheme:
The concrete steps of the method for extracting konjak ceramide from Rhizoma amorphophalli of the present invention are as follows:
(1) Rhizoma amorphophalli powder is broken into fine powder, then adds ethanol, solid-liquid ratio is 1.5:500-1200Kg/ml, then granulates;
(2) the Rhizoma amorphophalli granule of being prepared by step (1) adds supercritical CO
2in the extraction kettle of extraction equipment, to extraction kettle, separating still I, separating still II heats, and to cold machine and storage tank refrigeration, when extraction kettle temperature is 30-70 ℃, separating still I temperature is 40-65 ℃, when separating still II temperature is 30-60 ℃, open dioxide bottle, by high-pressure pump to extraction kettle, separating still pressurizes, when extraction kettle pressure is 20-40MPa, separating still I pressure is 6-18MPa, when separating still II pressure is 4-7MPa, closing carbon dioxide, pressure opening circulating valve, carry out extraction cycle, every circulation 30min, respectively from separating still I, II blowing, cycling extraction 1-2h.
In step (1), the concentration of ethanol is 95%, and solid-liquid ratio is preferably 1.5:1000Kg/ml.
In step (2), preferably extraction kettle temperature is 60 ℃, and pressure is 35MPa.
In step (2), preferable separate still I temperature is 50 ℃, and pressure is 15MPa.
In step (2), preferable separate still II temperature is 45 ℃, and pressure is 6MPa.
In step (2), preferably extraction time is 1.5h.
Technique effect of the present invention:
The method of extracting konjak ceramide from Rhizoma amorphophalli of the present invention is compared with solvent refluxing extraction method, supercritical CO
2extraction is compared with the C of reflux, extract,
6the yield of-ceramide is high by approximately 20%, and supercritical CO
2extraction product quality is better, at outward appearance, C
6the aspects such as-ceramide content are all better than solvent refluxing extraction method, and extraction process is simple simultaneously, efficiency is high, has solved the problems such as traditional reflux extraction solvent load is large, inflammable and explosive.
Accompanying drawing explanation
Fig. 1 is supercritical CO of the present invention
2extraction equipment schematic flow sheet.
In figure: 1-extraction kettle, 2-separating still I, 3-separating still II, 4-detached dowel, 5-heat exchanger, 6-high-pressure pump, 7-CO
2gas cylinder, the cold machine storage tank of 8-, 9-effusion meter.
The specific embodiment
The following examples are to describe in further detail of the present invention.
Embodiment 1
(1) Rhizoma amorphophalli powder is broken into fine powder, then adds ethanol, solid-liquid ratio is 1.5:500Kg/ml, then granulates;
(2) the Rhizoma amorphophalli granule of being prepared by step (1) adds supercritical CO
2in the extraction kettle of extraction equipment, extraction kettle, separating still I, separating still II are heated, and to cold machine and storage tank refrigeration, when extraction kettle temperature is 30 ℃, separating still I temperature is 40 ℃, when separating still II temperature is 30 ℃, opens dioxide bottle, by high-pressure pump, extraction kettle, separating still are pressurizeed, when extraction kettle pressure is 20MPa, separating still I pressure is 6MPa, when separating still II pressure is 4MPa, closing carbon dioxide, pressure opening circulating valve, carries out extraction cycle, every circulation 30min, respectively from separating still I, II blowing, cycling extraction 2h.
In step (1), the concentration of ethanol is 95%.
Embodiment 2
(1) Rhizoma amorphophalli powder is broken into fine powder, then adds ethanol, solid-liquid ratio is 1.5:1200Kg/ml, then granulates;
(2) the Rhizoma amorphophalli granule of being prepared by step (1) adds supercritical CO
2in the extraction kettle of extraction equipment, extraction kettle, separating still I, separating still II are heated, and to cold machine and storage tank refrigeration, when extraction kettle temperature is 70 ℃, separating still I temperature is 65 ℃, when separating still II temperature is 60 ℃, opens dioxide bottle, by high-pressure pump, extraction kettle, separating still are pressurizeed, when extraction kettle pressure is 40MPa, separating still I pressure is 18MPa, when separating still II pressure is 7MPa, closing carbon dioxide, pressure opening circulating valve, carries out extraction cycle, every circulation 30min, respectively from separating still I, II blowing, cycling extraction 1h.
In step (1), the concentration of ethanol is 95%.
Embodiment 3
(1) Rhizoma amorphophalli powder is broken into fine powder, then adds ethanol, solid-liquid ratio is 1.5:1000Kg/ml, then granulates;
(2) the Rhizoma amorphophalli granule of being prepared by step (1) adds supercritical CO
2in the extraction kettle of extraction equipment, extraction kettle, separating still I, separating still II are heated, and to cold machine and storage tank refrigeration, when extraction kettle temperature is 60 ℃, separating still I temperature is 50 ℃, when separating still II temperature is 45 ℃, opens dioxide bottle, by high-pressure pump, extraction kettle, separating still are pressurizeed, when extraction kettle pressure is 35MPa, separating still I pressure is 15MPa, when separating still II pressure is 6MPa, closing carbon dioxide, pressure opening circulating valve, carries out extraction cycle, every circulation 30min, respectively from separating still I, II blowing, cycling extraction 1.5h.
In step (1), the concentration of ethanol is 95%.
Comparative example (conventional solvent extraction)
Take Rhizoma amorphophalli powder, put into round-bottomed flask, add 95% ethanol, 80 ℃ of water-bath reflux, extract, 2 times, each 2h (adds 960ml95% ethanol for the first time, add for the second time 720ml95% ethanol), filter, merge extractive liquid,, 50 ℃ of concentrated by rotary evaporations are to anhydrous, obtain sepia oil-like extracts, weigh and calculated yield.
The calculating of yield
Yield is the important indicator of evaluating effect of extracting, and the computing formula of yield is as follows:
Crude extract yield=medical material crude extract quality ÷ medical material inventory * 100%
C6-Cer percentage composition % ÷ medical material inventory * 100% in C6-Cer yield=medical material crude extract quality * crude extract.
The yield of embodiment 1-3 is as shown in table 1:
Table 1
Take embodiment 3 as example contrast supercritical CO
2the quality that extraction and conventional solvent are extracted, result is as shown in table 2:
Table 2 supercritical CO
2the comparison of extraction and traditional reflux extraction
As can be seen from Table 2: supercritical CO
2extraction konjak ceramide crude extract yield is lower than reflux extraction, and C
6-Cer yield is higher, may contain the impurity large compared with pluripolarity due to the product of solvent extraction.Compare with traditional ethanol reflux extraction, supercritical extract is all better than traditional reflux extraction at aspects such as color and luster, ceramide content and yields.Therefore, adopt supercritical CO
2extraction konjak ceramide, is better than conventional extracting method.
Compare with conventional solvent reflux extraction, the supercritical CO of konjak ceramide of the present invention
2extraction process has following characteristics:
(1) extracting power is strong, and extraction efficiency is high, and yield is higher by approximately 20% than reflux extraction;
(2) extraction temperature is low, effectively protects temperature-sensitive effective ingredient;
(3) energy selective extraction and separated component, separable impurity in the time of extraction process;
(4) production technology is simple, does not need the techniques such as filtration;
(5) extraction is carried out under high pressure inert conditions, almost can kill aerobic microbiological completely, effectively guarantees and improve the quality of product
(6) avoid the use of organic solvent, reduce the consumption of ethanol.
Rhizoma amorphophalli supercritical CO
2extract analysis of volatile components
Embodiment 3 volatile ingredient preparation and konjak ceramide extract prepared by solvent method is carried out to makings chromatographic comparison:
GC conditions: chromatographic column is TR-1MS type 100% dimethyl polysiroxan fused-silica capillary column (30m * 0.25mm * 0.25 μ m); 250 ℃ of injector temperatures, do not shunt, and carrier gas is helium, flow velocity 1ml/min, sample size: 1 μ L.Mass spectrum condition: 280 ℃ of transfer tube temperature; 230 ℃ of ion source temperatures; EI ion source, electron energy 70ev; Full scan, sweep limits: 40-450.
Respectively the product of embodiment 3, commercially available prod and comparative example is carried out to component analysis, result is as shown in table 3:
3 kinds of different product volatile ingredient contrast tables of table 3
Known according to table 3 analysis result, there is larger difference in composition kind and number in three kinds of samples, Rhizoma amorphophalli supercritical CO
2extract main component is the materials such as Ethyl linoleate, ethyl palmitate, bean Gona-4-en-3-one, linolenic acid, elaidic acid ethyl ester; Rhizoma amorphophalli commercially available prod main component is the materials such as methyl linoleate, chionasterol, stigmasterol, vitamin E; Rhizoma amorphophalli reflux, extract, thing main component is diisobutyl phthalate, chionasterol, stigmasterol, 2,6-dimethyl-1,6-glycol-2, the materials such as 7-octadiene.
Rhizoma amorphophalli supercritical CO
2fatty acid in extract (ester) class material is mainly the compositions such as linolenic acid, Ethyl linoleate, ethyl palmitate, elaidic acid ethyl ester, and total relative amount reaches 71.68%; Rhizoma amorphophalli reflux, extract, material does not almost have this type of material; Commercially available Rhizoma amorphophalli extract mainly contains the compositions such as methyl linoleate, ethyl palmitate, elaidic acid ethyl ester, and relative amount is 31.61%.
Rhizoma amorphophalli supercritical CO
2in extract, main sterol is the materials such as bean Gona-4-en-3-one, bean sterone, 4-cholestene-3-ketone, and total relative amount reaches 12.93%; It is chionasterol, stigmasterol and glycerol deoxycholic acid that Rhizoma amorphophalli reflux, extract, owner wants sterol, and relative amount is 18.21%; Commercially available Rhizoma amorphophalli extract is mainly containing chionasterol and stigmasterol, and relative amount is 14.31%.
Squalene is a kind of lipid non-saponifiable matter.In three kinds of Rhizoma amorphophalli extracts, all contain Squalene, at supercritical CO
2relative amount in extract is 1.71%, is 1.84% in reflux, extract, thing, is 3.39% in commercially available extract.Squalene can promote hepatocellular regeneration and protect hepatocyte, thereby improve the function of liver; Squalene can impel the interior Superoxide dismutase of body and lactic acid dehydrogenase significantly to raise, and promotes lactic acid to decompose, and makes energy i (in vivo) metabolism vigorous, the fast quick-recovery of muscle power, timely allaying tiredness; Squalene energy blood circulation promoting, the content of reduction cholesterol and triglyceride, suppresses cholesterol in serum concentration, reduces lipoprotein concentration, and accelerates the discharge of cholesterol, can delay atherosclerotic formation, the generation of prevention cardiovascular and cerebrovascular disease.In addition, Squalene also has the effects such as defying age, antitumor.
Vitamin E is a kind of fatsoluble vitamin, claims again tocopherol, is one of topmost antioxidant.Relative amount in Rhizoma amorphophalli supercritical extract is 0.63%, is 6.00% in commercially available prod, and in reflux, extract, thing, quality testing is measured.Vitamin E has physiological function widely, and it can be by self being oxidized to fertility quinone, by active ROO
﹣be transformed into inactive ROOH, thereby interrupt the chain reaction of lipid peroxidation, suppress the peroxidation of lipid, Cell protection escapes injury; Promote sex hormones secretion, man's motility of sperm and quantity are increased, improve fertility; Maintain the permeability of blood capillary, increase blood flow, strengthen the ability of the cold resisting, and repair the cicatrix after vascular damaged, suppress hematoblastic gathering, the formation of anti-tampon.The Alcohol soluble composition major part of Rhizoma amorphophalli has physiological activity, identical or close with the part effect of Rhizoma amorphophalli, can infer that the part effect of Rhizoma amorphophalli may be relevant with its Alcohol soluble composition.For the further development and utilization of Rhizoma amorphophalli provides the foundation of science.
Although illustrated and described embodiments of the invention, for the ordinary skill in the art, be appreciated that without departing from the principles and spirit of the present invention and can carry out multiple variation, modification, replacement and modification to these embodiment, scope of the present invention is limited by claims and equivalent thereof.
Claims (6)
1. from Rhizoma amorphophalli, extract a method for konjak ceramide, it is characterized in that: the concrete steps of described method are as follows:
(1) Rhizoma amorphophalli powder is broken into fine powder, then adds ethanol, solid-liquid ratio is 1.5:500-1200Kg/ml, then granulates;
(2) the Rhizoma amorphophalli granule of being prepared by step (1) adds supercritical CO
2in the extraction kettle of extraction equipment, to extraction kettle, separating still I, separating still II heats, and to cold machine and storage tank refrigeration, when extraction kettle temperature is 30-70 ℃, separating still I temperature is 40-65 ℃, when separating still II temperature is 30-60 ℃, open dioxide bottle, by high-pressure pump to extraction kettle, separating still pressurizes, when extraction kettle pressure is 20-40MPa, separating still I pressure is 6-18MPa, when separating still II pressure is 4-7MPa, closing carbon dioxide, pressure opening circulating valve, carry out extraction cycle, every circulation 30min, respectively from separating still I, II blowing, cycling extraction 1-2h.
2. the method for extracting konjak ceramide from Rhizoma amorphophalli as claimed in claim 1, is characterized in that: in step (1), the concentration of ethanol is 95%, and solid-liquid ratio is 1.5:1000Kg/ml.
3. the method for extracting konjak ceramide from Rhizoma amorphophalli as claimed in claim 1, is characterized in that: in step (2), extraction kettle temperature is 60 ℃, and pressure is 35MPa.
4. the method for extracting konjak ceramide from Rhizoma amorphophalli as claimed in claim 1, is characterized in that: in step (2), separating still I temperature is 50 ℃, and pressure is 15MPa.
5. the method for extracting konjak ceramide from Rhizoma amorphophalli as claimed in claim 1, is characterized in that: in step (2), separating still II temperature is 45 ℃, and pressure is 6MPa.
6. the method for extracting konjak ceramide from Rhizoma amorphophalli as claimed in claim 1, is characterized in that: in step (2), extraction time is 1.5h.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410336065.3A CN104083556B (en) | 2014-07-15 | 2014-07-15 | A kind of method that konjak ceramide is extracted from konjaku |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410336065.3A CN104083556B (en) | 2014-07-15 | 2014-07-15 | A kind of method that konjak ceramide is extracted from konjaku |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104083556A true CN104083556A (en) | 2014-10-08 |
CN104083556B CN104083556B (en) | 2018-04-17 |
Family
ID=51631384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410336065.3A Active CN104083556B (en) | 2014-07-15 | 2014-07-15 | A kind of method that konjak ceramide is extracted from konjaku |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104083556B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105403633A (en) * | 2015-10-28 | 2016-03-16 | 广州中大南沙科技创新产业园有限公司 | Method for determining content of ceramide in konjak |
CN107721871A (en) * | 2017-10-20 | 2018-02-23 | 中山大学 | A kind of method that molecular distillation isolates and purifies konjak ceramide |
CN113413632A (en) * | 2021-07-08 | 2021-09-21 | 宁夏大学 | A lipid extract of Stellaria dichotoma and its preparation method |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103755583A (en) * | 2014-01-27 | 2014-04-30 | 广州市娇兰化妆品有限公司 | Method for extracting and separating ceramide in konjac flying powder |
-
2014
- 2014-07-15 CN CN201410336065.3A patent/CN104083556B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103755583A (en) * | 2014-01-27 | 2014-04-30 | 广州市娇兰化妆品有限公司 | Method for extracting and separating ceramide in konjac flying powder |
Non-Patent Citations (2)
Title |
---|
李佳等: "微生物发酵米糠制备神经酰胺", 《化学研究与应用》 * |
葛发欢主编: "《中药超临界二氧化碳萃取技术研究》", 31 March 2014, 中国医药科技出版社 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105403633A (en) * | 2015-10-28 | 2016-03-16 | 广州中大南沙科技创新产业园有限公司 | Method for determining content of ceramide in konjak |
CN105403633B (en) * | 2015-10-28 | 2018-05-11 | 广州中大南沙科技创新产业园有限公司 | Ceramide content assay method in konjaku |
CN107721871A (en) * | 2017-10-20 | 2018-02-23 | 中山大学 | A kind of method that molecular distillation isolates and purifies konjak ceramide |
CN113413632A (en) * | 2021-07-08 | 2021-09-21 | 宁夏大学 | A lipid extract of Stellaria dichotoma and its preparation method |
CN113413632B (en) * | 2021-07-08 | 2022-06-03 | 宁夏大学 | A lipid extract of Stellaria dichotoma and its preparation method |
Also Published As
Publication number | Publication date |
---|---|
CN104083556B (en) | 2018-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106860492B (en) | Preparation method of cannabinol compound | |
CN102424770A (en) | Extraction technology of perilla frutescens essential oil | |
CN105623842A (en) | Method for subcritical extraction of moringa oleifera seed oil and method for testing location distribution of triglyceride in moringa oleifera seed oil | |
CN109609276A (en) | A kind of extracting method of oil camphor tree leaf essential oil | |
CN102876456A (en) | Method for extracting volatile oil and alkaloid from pepper by using subcritical fluid | |
CN106187977A (en) | A kind of method extracting Garcinia mangostana shell procyanidins | |
CN103432562A (en) | Method for extracting fresh ginger polyphenol from fresh ginger | |
CN102100875A (en) | Process method for microwave assistant supercritical extraction of active ingredients of curcuma | |
CN104083556A (en) | Method for extracting konjak ceramide from konjak | |
CN102925497A (en) | Method for preparing high-purity resveratrol from polygonum cuspidatum | |
CN102942637B (en) | Method for increasing extraction rate of wide cactus polysaccharide | |
CN104140885B (en) | Oil plant seed is that raw material prepares the method with oxidation resistance long chain fat acid esters | |
CN105878323A (en) | Method using ultrasonically-assisted supercritical extraction rectification to purify cynarin in globe artichoke | |
CN101328201A (en) | Method for extracting betulin from birch bark | |
CN101982191A (en) | Method for extracting fat-reducing compound functional materials from lotus leaves | |
CN101863764A (en) | Method for extracting and separating coixenolide and coix seed oil step-by-step by using supercritical CO2 | |
CN107033045B (en) | A kind of preparation method of high-purity natural garlic 4,5,9-trithiadodeca-1,6,11-triene 9-oxide | |
CN100451030C (en) | Process of preparing ganoderma tricterpinyl acid and ganoderma polyose from ganoderma | |
CN104073355A (en) | Extraction method of pogostemon cablin essential oil | |
CN102061219A (en) | Method for extracting tea seed oil | |
CN102219669B (en) | Method for extracting purslane linolenic acid with supercritical CO2 fluid | |
CN106187978A (en) | A kind of method extracting pitaya peel procyanidins | |
CN106187976A (en) | A kind of method extracting Rhizoma Steudnerae Henryanae procyanidins | |
CN102399622A (en) | Method for preparing bitter almond extract product | |
CN102432419B (en) | Method for extracting and separating beta-elemene from Eupatorium adenophorum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |